KZIA · Kazia Therapeutics

Kazia Therapeutics Limited, through its subsidiaries, operates as an oncology-focused biotechnology company in Israel. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical teratoid rhabdoid tumors. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group; as well as licence agreement with Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Three International Towers, Sydney, NSW, 2000, Australia
Biotechnology
Healthcare

Market Cap

60.68M

52 Wk Range

$4.86 - $17.40

Previous Close

$5.31

Open

$5.25

Volume

226,313

Day Range

$5.25 - $5.75

Enterprise Value

40.06M

Cash

69.46M

Avg Qtr Burn

N/A

Insider Ownership

15.42%

Institutional Own.

45.98%

Qtr Updated

N/A